Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378386 · ClinicalTrials.gov registry record
ALTERRA Post-Approval Study
A clinical trial of Tetralogy of Fallot and Pulmonary Regurgitation, sponsored by Edwards Lifesciences.
- Active
- Registry status
- 150
- Enrollment target
- 20
- Study locations
NCT05378386 is a study of Tetralogy of Fallot and Pulmonary Regurgitation that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 150 participants, below the 168-participant average among 7 other Tetralogy of Fallot trials with a reported enrollment target (11% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT05378386, a study of Tetralogy of Fallot and Pulmonary Regurgitation, is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
Conditions Studied
Interventions
- DEVICE Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System
Study Locations (20)
California
- Cedars Sinai Medical Center - Los Angeles
- Rady Children's Hospital - San Diego
- Stanford University - Stanford
Florida
- UF Health Shands Hospital - Gainesville
- St. Joseph's Children's Hospital - Tampa
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University - New York
Ohio
- Cincinnati Children's Hospital - Cincinnati
- Nationwide Children's Hospital - Columbus
Texas
- Medical City Dallas - Dallas
- Children's Memorial Hermann Hospital - Houston
Alabama
- Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Colorado Children's Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2035-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378386
The ClinicalTrials.gov registry entry for NCT05378386 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 7 other Tetralogy of Fallot trials with a reported enrollment target (11% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Tetralogy of Fallot appearing as the primary indexed condition, and to 1 intervention - of which Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System is the first listed.
NCT05378386 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05378386 about?
NCT05378386 is a clinical study titled "ALTERRA Post-Approval Study". This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting
What is the current status of trial NCT05378386?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2022-05-12. Estimated completion is 2035-07.
What conditions does trial NCT05378386 study?
This clinical trial studies the following conditions: Tetralogy of Fallot, Pulmonary Regurgitation, Complex Congenital Heart Defect, Pulmonary Valve Insufficiency, RVOT Anomaly.
What interventions are being tested in trial NCT05378386?
The interventions under investigation include: Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System (DEVICE).
Who is sponsoring clinical trial NCT05378386?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378386 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tetralogy of Fallot
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
RECRUITING
-
Beta-blocker Administration for Cardiomyocyte Division
RECRUITING · Phase 1
-
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development
RECRUITING
-
ALTERRA: SAPIEN 3 THV With the Alterra Adaptive Prestent
ACTIVE NOT RECRUITING · NA
-
Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction
ACTIVE NOT RECRUITING · NA
-
Assessment of Right Ventricular Volume in Tetralogy of Fallott (TOF) Patients
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.